Akshay Sharma, Jacques-Emmanuel Galimard, Angharad Pryce, Senthil Velan Bhoopalan, Arnaud Dalissier, Jean-Hugues Dalle, Franco Locatelli, Charlotte Jubert, Oana Mirci-Danicar, Vassiliki Kitra-Roussou, Yves Bertrand, Franca Fagioli, Fanny Rialland, Alessandra Biffi, Robert F Wynn, Gérard Michel, Francesco Paolo Tambaro, Ali Al-Ahmari, Abdelghani Tbakhi, Caroline L Furness, Miguel Angel Diaz, Petr Sedlacek, Ivana Bodova, Maura Faraci, Kanchan Rao, Katharina Kleinschmidt, Arnaud Petit, Brenda Gibson, Neel S Bhatt, Krzysztof Kalwak, Selim Corbacioglu
Poor-risk (PR) cytogenetic/molecular abnormalities generally direct pediatric patients with acute myeloid leukemia (AML) to allogeneic hematopoietic stem cell transplant (HSCT). We assessed the predictive value of cytogenetic risk classification at diagnosis with respect to post-HSCT outcomes in pediatric patients. Patients younger than 18 years at the time of their first allogeneic HSCT for AML in CR1 between 2005 and 2022 who were reported to the European Society for Blood and Marrow Transplantation registry were subgrouped into four categories...
January 15, 2024: Bone Marrow Transplantation